Centocor Files Application for Approval of Arthritis Drug
Posted on: Monday, 30 June 2008, 12:03 CDT
Centocor has submitted a biologics license application to the FDA requesting the approval of golimumab as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Golimumab, Centocor's next-generation human anti-TNF-alpha monoclonal antibody, is being studied as an every four week subcutaneous injection and is also being studied as an intravenous (IV) infusion therapy.
Jerome Boscia, senior vice president, clinical R&D, Centocor, said: "This submission marks a major milestone in the clinical development program of golimumab, and we look forward to working with the FDA to bring golimumab to market."
Source: Datamonitor
Related Articles
- Golimumab and Actemra Will Be Two of the Most Successful Emerging Novel Agents in the Rheumatoid Arthritis Drug Treatment Market
- Phase 3 Data Show Efficacy of Golimumab in Patients With Active Rheumatoid Arthritis Previously Treated With Anti-TNF Agents
- Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
- Centocor and Schering-Plough Submit MAA for Arthritis Drug
- Centocor, Inc. And Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
- Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients With Psoriatic Arthritis
- New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
- Anti-TNF Golimumab (CNTO 148) Continues to Show Promise in Phase 2 Rheumatoid Arthritis Study
User Comments (0)
RSS Feeds